Comparison of SimoaTM and EllaTM to assess serum neurofilament-light chain in multiple sclerosis

Ann Clin Transl Neurol. 2021 May;8(5):1141-1150. doi: 10.1002/acn3.51355. Epub 2021 Apr 8.

Abstract

We compared SimoaTM and EllaTM immunoassays to assess serum neurofilament-light chain levels in 203 multiple sclerosis patients from the OFSEP HD study. There was a strong correlation (ρ = 0.86, p < 0.0001) between both platforms. The EllaTM instrument overestimated values by 17%, but as the data were linear (p = 0.57), it was possible to apply a correction factor to EllaTM results. As for SimoaTM , serum neurofilament-light chain levels measured by EllaTM were correlated with age and EDSS and were significantly higher in active multiple sclerosis, suggesting that these assays are equivalent and can be used in routine clinical practice.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Immunoassay / standards*
  • Multiple Sclerosis / blood*
  • Multiple Sclerosis / diagnosis*
  • Neurofilament Proteins / blood*

Substances

  • Neurofilament Proteins
  • neurofilament protein L

Grants and funding

This work was funded by CHU de Nimes grant ; Agence Nationale de la Recherche grant ANR‐10‐COHO‐002.